Abstract:Background Congenital heart disease (CHD) represents the most widespread congenital birth defect among neonates worldwide, leading to substantial expenses and contributing significantly to premature death caused by birth defects. Despite the significance of CHD, research on its etiology remains limited and has failed to provide substantial evidence for the molecular basis of the disease. With the advancement of next-generation sequencing (NGS), genetic screening has become increasingly accessible, offering a greater capability for identifying potential genetic variants associated with CHD. Case presentation Exome sequencing and variant analysis of TMEM260 were performed to obtain genetic data, and clinical characteristics were determined. A complex and severe form of CHD, comprising a persistent truncus arteriosus type I, ventricular septal defect, right aortic arch, as well as critical neurodevelopmental delay and neurological dysfunction, was observed in a patient. This proband presented global muscle hypotonia and a significant delay in gross and fine motor development. Cranial computed tomography scanning showed the presence of bilateral apical, occipital, and temporal subdural effusions; slightly wider bilateral lateral ventricles and annular cisterns; and bilateral cerebral hemispheric parenchyma atrophy. Upon genetic analysis of the patient, a novel homozygous mutation was identified in the TMEM260 gene. The mutation, c.1336_1339DEL, was found to be homozygous and resulted in a frameshift mutation, causing a p.L447Vfs * 9 amino acid change. This mutation led to the deletion of a TCTC sequence from positions 1336 to 1339 in the TMEM260 gene, changing leucine to valine at amino acid 447 and introducing a stop codon after the ninth amino acid. This structural deletion in the TMEM260 protein resulted in the loss of gene function. Conclusion This case report presents a newly discovered variant site in the TMEM260 gene and reinforces the relationship between TMEM260 molecular function and differentiation of mesoderm and ectoderm. Furthermore, our findings broaden the spectrum of variants in the TMEM260 gene and contribute to advancing the genetic understanding of CHD.

Research progress on TMEM16F and related diseases

TMEM175: A Lysosomal Ion Channel Associated with Neurological Diseases

TMEM63 mechanosensitive ion channels: Activation mechanisms, biological functions and human genetic disorders

Modulating Ca2+ signals: a common theme for TMEM16, Ist2, and TMC

TMEM16 proteins: Ca2+‑activated chloride channels and phospholipid scramblases as potential drug targets (Review)

The Role of Transmembrane Protein 16A (TMEM16A) in Pulmonary Hypertension.

Transmembrane proteins with unknown function (TMEMs) as ion channels: electrophysiological properties, structure, and pathophysiological roles

Physiological and pathological functions of TMEM106B in neurodegenerative diseases

TMEM16A ion channel: A novel target for cancer treatment

Anoctamin Pharmacology

TMEM16A:A Type of Calcium-activated Chloride Channel

Studies on Expression and Function of the TMEM16A Calcium-Activated Chloride Channel.

A comprehensive search for calcium binding sites critical for TMEM16A calcium-activated chloride channel activity

The Ca<SUP>2+</SUP>-activated chloride channel ANO1/TMEM16A: An emerging therapeutic target for epithelium-originated diseases?

The TMEM16A channel as a potential therapeutic target in vascular disease

Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders

Tmem16F Forms a Ca2+-Activated Cation Channel Required for Lipid Scrambling in Platelets During Blood Coagulation

TMEM16F scramblase regulates angiogenesis via endothelial intracellular signaling

Intracellular TMEM16A is necessary for myogenesis of skeletal muscle

Advances in Anoctamin 1: A Potential New Drug Target in Medicinal Chemistry

A novel homozygous variant of TMEM260 induced cardiac malformation and neurodevelopmental abnormality: case report and literature review